Levine Mark S.

General CounselFlexion Therapeutics Inc (FLXN) · full profile →Form 4 · filed Nov 19, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
1 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 19, 2021Disposed to issuer(D)133K$8.50$1.1M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 19, 2021Disposed to issuer(D)125K0
Nov 19, 2021Disposed to issuer(D)33K0
Nov 19, 2021Disposed to issuer(D)20K0
Nov 19, 2021Disposed to issuer(D)16K0
Nov 19, 2021Disposed to issuer(D)18K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-21-065712) within minutes of acceptance. Every field above traces to the original document. Verify it directly: